Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ICARES Medicus, Inc. (6612.TWO)
TWD72.80
+0.50 (+0.69%)
TW TWO Healthcare Medical - Instruments & Supplies
Address
No. 16, Shengyi Road
Zhubei, TW
Zhubei, TW
CEO
Tan-Li Chen
Website
icaresmedicus.com
IPO
2016-12-27
ISIN TW0006612005
Description
ICARES Medicus, Inc. operates as a dedicated nano-medical materials company, engaging in the entire lifecycle from innovation and production to global distribution of advanced ophthalmic medical materials. Its core offerings encompass a range of ocular solutions, most notably intraocular lenses (IOLs) designed to correct visual impairments such as cataracts, nearsightedness (myopia), farsightedness (hyperopia), age-related vision loss (presbyopia), and astigmatism. Additionally, the company supplies sophisticated surgical implantation systems along with comprehensive technical support services. Established in 2011, ICARES Medicus, Inc. maintains its headquarters in Zhubei, Taiwan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD72.80
+0.50 (+0.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
39.6K
Beta
0.28
Float Shares
22.52M
Free Float %
47.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.23% | +6.47% | +4.78% | -14.32% | -2.03% | -34.72% | -44.89% | +40.17% | +75.69% | +75.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
72.80
DCF (Unlevered)
883.92
+1,114.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.68
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+31.5% ★ Q1'26: +0.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-50.0% Q1'26: -19.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-5.8% Q1'26: -6.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+11.4% Q1'26: +12.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.5% Q1'26: +4.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-94.0% ★ Q1'26: -37.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.83× ★ Q1'26: 2.68× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
329.28M
est: 336.00M (-2.0%)
|
419.36M
est: 380.00M (+10.4%)
|
362.67M
est: 422.00M (-14.1%)
|
393.92M
est: 411.00M (-4.2%)
|
511.85M
est: 650.00M (-21.3%)
|
605.45M
est: 650.00M (-6.9%)
|
859.79M
est: 650.00M (+32.3%)
|
1.13B
est: 336.00M (+236.6%)
|
336.00M
336.00M – 336.00M
+0.0% YoY
|
380.00M
380.00M – 380.00M
+13.1% YoY
|
422.00M
422.00M – 422.00M
+11.1% YoY
|
411.00M
411.00M – 411.00M
-2.6% YoY
|
650.00M
650.00M – 650.00M
+58.2% YoY
|
| EBITDA |
111.42M
est: 97.99M (+13.7%)
|
122.02M
est: 110.82M (+10.1%)
|
95.81M
est: 123.07M (-22.2%)
|
105.87M
est: 119.87M (-11.7%)
|
174.42M
est: 189.57M (-8.0%)
|
164.20M
est: 189.57M (-13.4%)
|
269.39M
est: 187.22M (+43.9%)
|
278.34M
est: 96.78M (+187.6%)
|
96.78M
96.78M – 96.78M
+0.0% YoY
|
109.45M
109.45M – 109.45M
+13.1% YoY
|
121.55M
121.55M – 121.55M
+11.1% YoY
|
118.38M
118.38M – 118.38M
-2.6% YoY
|
187.22M
187.22M – 187.22M
+58.2% YoY
|
| EBIT |
100.65M
est: 73.66M (+36.6%)
|
105.55M
est: 83.31M (+26.7%)
|
74.74M
est: 92.52M (-19.2%)
|
76.19M
est: 90.11M (-15.4%)
|
143.68M
est: 142.50M (+0.8%)
|
120.46M
est: 142.50M (-15.5%)
|
180.35M
est: 130.49M (+38.2%)
|
128.58M
est: 67.45M (+90.6%)
|
67.45M
67.45M – 67.45M
+0.0% YoY
|
76.29M
76.29M – 76.29M
+13.1% YoY
|
84.72M
84.72M – 84.72M
+11.1% YoY
|
82.51M
82.51M – 82.51M
-2.6% YoY
|
130.49M
130.49M – 130.49M
+58.2% YoY
|
| Net Income |
70.45M
est: 110.25M (-36.1%)
|
81.02M
est: 112.79M (-28.2%)
|
51.91M
est: 106.64M (-51.3%)
|
58.60M
est: 91.17M (-35.7%)
|
128.91M
est: 167.49M (-23.0%)
|
97.73M
est: 167.49M (-41.7%)
|
103.12M
est: 9.08M (+1,035.8%)
|
3.07M
est: 5.98M (-48.6%)
|
5.98M
5.98M – 5.98M
+0.0% YoY
|
6.11M
6.11M – 6.11M
+2.3% YoY
|
5.78M
5.78M – 5.78M
-5.5% YoY
|
4.94M
4.94M – 4.94M
-14.5% YoY
|
9.08M
9.08M – 9.08M
+83.7% YoY
|
| SGA |
104.58M
est: 106.26M (-1.6%)
|
122.58M
est: 120.18M (+2.0%)
|
116.32M
est: 133.46M (-12.8%)
|
127.00M
est: 129.98M (-2.3%)
|
157.23M
est: 205.57M (-23.5%)
|
186.31M
est: 205.57M (-9.4%)
|
277.97M
est: 199.06M (+39.6%)
|
306.10M
est: 102.90M (+197.5%)
|
102.90M
102.90M – 102.90M
+0.0% YoY
|
116.37M
116.37M – 116.37M
+13.1% YoY
|
129.24M
129.24M – 129.24M
+11.1% YoY
|
125.87M
125.87M – 125.87M
-2.6% YoY
|
199.06M
199.06M – 199.06M
+58.2% YoY
|
| EPS |
1.82
est: 2.33 (-22.1%)
|
1.98
est: 2.39 (-17.0%)
|
1.26
est: 2.26 (-44.0%)
|
1.42
est: 1.93 (-26.5%)
|
3.46
est: 3.55 (-2.3%)
|
2.55
est: 3.55 (-27.9%)
|
2.20
est: 3.22 (-31.7%)
|
1.09
est: 2.12 (-48.6%)
|
2.12
2.12 – 2.12
+0.0% YoY
|
2.17
2.17 – 2.17
+2.3% YoY
|
2.05
2.05 – 2.05
-5.5% YoY
|
1.75
1.75 – 1.75
-14.5% YoY
|
3.22
3.22 – 3.22
+83.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
113.80M
OE per share TTM
38.62
Owner's Yield
5.34%
Maintenance CapEx ratio
38.51%
Maint CapEx / Avg PPE
24.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 50.6K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.67M
Shares Outstanding
47.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carl Robert Cummings | President of Major Subsidiary | — | male |
| Junming Lin | Vice President of R&D and Operations | — | — |
| Tan-Li Chen | Vice President and Head of Finance & Accounting Department | — | female |
| Wen-Chu Tseng | Chief R&D Officer & Director | — | male |
| Ying-Zong Yan | Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6612.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
